113 related articles for article (PubMed ID: 23272129)
1. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.
Kao YC; Jiang SJ; Pan WA; Wang KC; Chen PK; Wei HJ; Chen WS; Chang BI; Shi GY; Wu HL
PLoS One; 2012; 7(12):e51647. PubMed ID: 23272129
[TBL] [Abstract][Full Text] [Related]
2. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers.
Zanivan S; Maione F; Hein MY; Hernández-Fernaud JR; Ostasiewicz P; Giraudo E; Mann M
Mol Cell Proteomics; 2013 Dec; 12(12):3599-611. PubMed ID: 23979707
[TBL] [Abstract][Full Text] [Related]
3. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
[TBL] [Abstract][Full Text] [Related]
4. CD93 maintains endothelial barrier function and limits metastatic dissemination.
Vemuri K; de Alves Pereira B; Fuenzalida P; Subashi Y; Barbera S; van Hooren L; Hedlund M; Pontén F; Lindskog C; Olsson AK; Lugano R; Dimberg A
JCI Insight; 2024 Mar; 9(7):. PubMed ID: 38441970
[TBL] [Abstract][Full Text] [Related]
5. Blockade of CD93 in pleural mesothelial cells fuels anti-lung tumor immune responses.
Zhang C; Nan X; Zhang B; Wu H; Zeng X; Song Z; Li S; Wang J; Xie S; Zhang G; Xiu H; Wang J; Guo J; Wang P; Cai Z; Zhen Y; Shen Y
Theranostics; 2024; 14(3):1010-1028. PubMed ID: 38250037
[No Abstract] [Full Text] [Related]
6. CD93 Ameliorates Diabetic Wounds by Promoting Angiogenesis via the p38MAPK/MK2/HSP27 Axis.
Xu Y; Jia Y; Wu N; Wang J; He L; Yang D
Eur J Vasc Endovasc Surg; 2023 Nov; 66(5):707-721. PubMed ID: 37295599
[TBL] [Abstract][Full Text] [Related]
7. Screening and construction of nanobodies against human CD93 using phage libraries and study of their antiangiogenic effects.
Miao H; Wu Y; Ouyang H; Zhang P; Zheng W; Ma X
Front Bioeng Biotechnol; 2024; 12():1372245. PubMed ID: 38751868
[TBL] [Abstract][Full Text] [Related]
8. Membrane-associated CD93 regulates leukocyte migration and C1q-hemolytic activity during murine peritonitis.
Greenlee-Wacker MC; Briseño C; Galvan M; Moriel G; Velázquez P; Bohlson SS
J Immunol; 2011 Sep; 187(6):3353-61. PubMed ID: 21849679
[TBL] [Abstract][Full Text] [Related]
9. A heparin mimetic isolated from a marine shrimp suppresses neovascularization.
Dreyfuss JL; Regatieri CV; Lima MA; Paredes-Gamero EJ; Brito AS; Chavante SF; Belfort R; Farah ME; Nader HB
J Thromb Haemost; 2010 Aug; 8(8):1828-37. PubMed ID: 20492474
[TBL] [Abstract][Full Text] [Related]
10. Role of CD93 in Health and Disease.
Tossetta G; Piani F; Borghi C; Marzioni D
Cells; 2023 Jul; 12(13):. PubMed ID: 37443812
[TBL] [Abstract][Full Text] [Related]
11. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
bioRxiv; 2023 Jun; ():. PubMed ID: 37333140
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.
Li Y; Fu L; Wu B; Guo X; Shi Y; Lv C; Yu Y; Zhang Y; Liang Z; Zhong C; Han S; Xu F; Tian Y
Cancer Cell Int; 2023 Sep; 23(1):189. PubMed ID: 37660019
[TBL] [Abstract][Full Text] [Related]
13. [Research progress of CD93
Niu C; Sun S; Liu D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):267-272. PubMed ID: 38512037
[TBL] [Abstract][Full Text] [Related]
14. The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.
Orlandini M; Galvagni F; Bardelli M; Rocchigiani M; Lentucci C; Anselmi F; Zippo A; Bini L; Oliviero S
Oncotarget; 2014 May; 5(9):2750-60. PubMed ID: 24809468
[TBL] [Abstract][Full Text] [Related]
15. CD93 and GIPC expression and localization during central nervous system inflammation.
Liu C; Cui Z; Wang S; Zhang D
Neural Regen Res; 2014 Nov; 9(22):1995-2001. PubMed ID: 25598782
[TBL] [Abstract][Full Text] [Related]
16. CD93 gene polymorphism is associated with disseminated colorectal cancer.
Olsen RS; Lindh M; Vorkapic E; Andersson RE; Zar N; Löfgren S; Dimberg J; Matussek A; Wågsäter D
Int J Colorectal Dis; 2015 Jul; 30(7):883-90. PubMed ID: 26008729
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD93 levels in patients with acute myocardial infarction and its implication on clinical outcome.
Youn JC; Yu HT; Jeon JW; Lee HS; Jang Y; Park YW; Park YB; Shin EC; Ha JW
PLoS One; 2014; 9(5):e96538. PubMed ID: 24801400
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.
Sun Y; Chen W; Torphy RJ; Yao S; Zhu G; Lin R; Lugano R; Miller EN; Fujiwara Y; Bian L; Zheng L; Anand S; Gao F; Zhang W; Ferrara SE; Goodspeed AE; Dimberg A; Wang XJ; Edil BH; Barnett CC; Schulick RD; Chen L; Zhu Y
Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321321
[TBL] [Abstract][Full Text] [Related]
19. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
[TBL] [Abstract][Full Text] [Related]
20. The C-type lectin CD93 controls endothelial cell migration via activation of the Rho family of small GTPases.
Barbera S; Lugano R; Pedalina A; Mongiat M; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
Matrix Biol; 2021 May; 99():1-17. PubMed ID: 34062268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
